Helmholtz Zentrum München

HMGU

As German Research Center for Environmental Health, HelmholtzZentrum München (HMGU) seeks to further the development of prevention and therapy strategies for diabetes mellitus – with a special focus on personalized medicine. The Helmholtz Diabetes Center understands diabetes to be a complex, systemic disease in which both genetic and environmental factors – in particular lifestyle – interact. Here basic research and clinical research are intertwined in close interdisciplinary cooperation with the Munich universities.


Institutes and associated groups

  • Institute of Diabetes Research: Prof. Dr. Anette-Gabriele Ziegler, PD Dr. Peter Achenbach
  • Institute of Diabetes and Obesity: Dr. Timo Müller, Dr. Paul Pfluger
  • Institute of Diabetes and Cancer: Prof. Dr. Stephan Herzig
  • Institute of Diabetes and Regeneration Research: Prof. Dr. Heiko Lickert, Dr. Ingo Burtscher
  • Institute of Experimental Genetics: Prof. Dr. Martin Hrabě de Angelis, Prof. Dr. Johannes Beckers, Dr. Raffaele Teperino
  • Institute of Computational Biology: Prof. Dr. Dr. Fabian Theis, Dr. Michael Menden (DZD-Core Unit Computational Biology)
  • Clinical Cooperation Group Nutrigenomics und Typ-2-Diabetes mellitus, TUM: Prof. Dr. Hans Hauner
  • Clinical Cooperation Group Prediction and Subclassification of Typ-2-Diabetes mellitus, LMU: Prof. Dr. Jochen Seissler, PD Dr. Andreas Lechner
  • Institute of Epidemiology: Prof. Dr. Annette Peters, Dr. Christian Gieger, Dr. Harald Grallert, Prof. Dr. Karl-Heinz Ladwig, PD Dr. Barbara Thorand, Dr. Rui Wang-Sattler
  • Institut of Health Economics and Health Care Management: Prof. Dr. Reiner Leidl, Dr. Michael Laxy
  • Genom Analysis Center: Prof. Dr. Jerzy Adamski
  • Institute of Human Genetics: Prof. Dr. Thomas Meitinger, Dr. Tim Strom
  • Research Unit Analytical BioGeoChemistry: Prof. Dr. Dr. Philippe Schmitt-Kopplin
  • Institute of Translational Stem Cell Research: Prof. Dr. Henrik Semb

 

Contribution to the DZD research program

  • Establishment and characterization of relevant mouse models
  • Development of a vaccine strategy for type 1 diabetics
  • Identification of early predictive metabolic markers, personalized type 2 diabetes risk prognosis
  • Differentiation of embryonic stem cells into insulin-secreting cells
  • Drug development
  • Computational Biology
  • Participation in the clinical studies of the DZD
  • KORA-Cohort

Speaker

Prof. Dr. Dr. h.c. mult.
Martin Hrabě de Angelis

Director of the Institute of Experimental Genetics
Helmholtz Zentrum München

Contact

Helmholtz Zentrum München – German Research Center for Environmental Health
Ingolstädter Landstrasse 1
85764 Neuherberg
Germany

+49 (0)89 3187 3302

hrabe(at)helmholtz-muenchen.de

To find out more, listen to the podcast (German only) with Professor Hrabĕ de Angelis discussing important aspects of research conducted in the DZD.